BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma
NCT06745687
·
clinicaltrials.gov ↗
NA
Phase
NOT_YET_RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
High Risk Smoldering Multiple Myeloma
Interventions
DRUG:
CM336
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Collaborators
[object Object]